ArticleCancer immunology, immunotherapy : CII2018

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Zachary J Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.